SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Cecilia Mattsson, Peder Svensson, Clas Sonesson, A novel series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones as selective monoamine oxidase (MAO) A inhibitors, European Journal of Medicinal Chemistry, 2014, 73, 177

    CrossRef

  2. 2
    Weidong Le, Pavani Sayana, Joseph Jankovic, Animal Models of Parkinson’s Disease: A Gateway to Therapeutics?, Neurotherapeutics, 2014, 11, 1, 92

    CrossRef

  3. 3
    Anne-Catherine Vijverman, Susan H Fox, New treatments for the motor symptoms of Parkinson’s disease, Expert Review of Clinical Pharmacology, 2014, 7, 6, 761

    CrossRef

  4. 4
    Eva Schaeffer, Andrea Pilotto, Daniela Berg, Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease, CNS Drugs, 2014, 28, 12, 1155

    CrossRef

  5. 5
    Rupam Borgohain, J. Szasz, P. Stanzione, C. Meshram, M. Bhatt, D. Chirilineau, F. Stocchi, V. Lucini, R. Giuliani, E. Forrest, P. Rice, R. Anand, Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations, Movement Disorders, 2014, 29, 2
  6. 6
    Livia Dézsi, László Vécsei, Safinamide for the treatment of Parkinson's disease, Expert Opinion on Investigational Drugs, 2014, 23, 5, 729

    CrossRef

  7. 7
    Rukmini Mridula Kandadai, Shaik Afshan Jabeen, Meena A Kanikannan, Rupam Borgohain, Safinamide for the treatment of Parkinson’s disease, Expert Review of Clinical Pharmacology, 2014, 7, 6, 747

    CrossRef

  8. 8
    Fabrizio Stocchi, Therapy for Parkinson’s Disease: What is in the Pipeline?, Neurotherapeutics, 2014, 11, 1, 24

    CrossRef

  9. 9
    Rajesh Pahwa, Kelly E. Lyons, Treatment of early Parkinsonʼs disease, Current Opinion in Neurology, 2014, 27, 4, 442

    CrossRef

  10. 10
    Adolfo Ramirez-Zamora, Eric Molho, Treatment of motor fluctuations in Parkinson’s disease: recent developments and future directions, Expert Review of Neurotherapeutics, 2014, 14, 1, 93

    CrossRef

  11. 11
    Rupam Borgohain, Jozsef Szasz, Paolo Stanzione, Chandrashekhar Meshram, Mohit H. Bhatt, Dana Chirilineau, Fabrizio Stocchi, Valentina Lucini, Rodolfo Giuliani, Emma Forrest, Patricia Rice, Ravi Anand, Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease, Movement Disorders, 2014, 29, 10
  12. 12
    Alison J Yarnall, What are the priorities in Parkinson's disease clinical research? A focus on motor complications, gait and cognition, Neurodegenerative Disease Management, 2014, 4, 2, 127

    CrossRef

  13. 13
    Lars Brichta, Paul Greengard, Marc Flajolet, Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems, Trends in Neurosciences, 2013, 36, 9, 543

    CrossRef

  14. 14
    Thomas Müller, Current status of safinamide for the drug portfolio of Parkinson’s disease therapy, Expert Review of Neurotherapeutics, 2013, 13, 9, 969

    CrossRef

  15. 15
    Chiara Leuratti, Marco Sardina, Paolo Ventura, Alessandro Assandri, Markus Müller, Martin Brunner, Disposition and Metabolism of Safinamide, a Novel Drug for Parkinson's Disease, in Healthy Male Volunteers, Pharmacology, 2013, 92, 3-4, 207

    CrossRef

  16. 16
    Manuela Pilleri, Konstantinos Koutsikos, Angelo Antonini, Is there room for new non-dopaminergic treatments in Parkinson’s disease?, Journal of Neural Transmission, 2013, 120, 2, 349

    CrossRef

  17. 17
    A. H. V. Schapira, F. Stocchi, R. Borgohain, M. Onofrj, M. Bhatt, P. Lorenzana, V. Lucini, R. Giuliani, R. Anand, Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease, European Journal of Neurology, 2013, 20, 2
  18. 18
    Susan H. Fox, Non-dopaminergic Treatments for Motor Control in Parkinson’s Disease, Drugs, 2013, 73, 13, 1405

    CrossRef

  19. 19
    Lorraine V. Kalia, Jonathan M. Brotchie, Susan H. Fox, Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials, Movement Disorders, 2013, 28, 2
  20. 20
    Rupam Borgohain, Rukmini Mridula Kandadai, Safinamide: a novel anti-Parkinsonian drug with multiple actions, Neurodegenerative Disease Management, 2013, 3, 3, 231

    CrossRef

  21. 21
    Francisco Grandas, Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson’s disease, Expert Review of Neurotherapeutics, 2013, 13, 12, 1343

    CrossRef

  22. 22
    Samantha Podurgiel, Lyndsey E. Collins-Praino, Samantha Yohn, Patrick A. Randall, Arthur Roach, Christophe Lobianco, John D. Salamone, Tremorolytic effects of safinamide in animal models of drug-induced parkinsonian tremor, Pharmacology Biochemistry and Behavior, 2013, 105, 105

    CrossRef

  23. 23
    Susan H Fox, Lorraine V Kalia, Parkinson’s Disease: Medical and Surgical Treatment, 2013,

    CrossRef

  24. 24
    Fernando L. Pagan, Jill Giordano Farmer, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  25. 25
    Fernando Pagan, Jill Farmer, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  26. 26
    Werner Poewe, Philipp Mahlknecht, Joseph Jankovic, Emerging therapies for Parkinsonʼs disease, Current Opinion in Neurology, 2012, 25, 4, 448

    CrossRef

  27. 27
    Spyros N Deftereos, Evie Dodou, Christos Andronis, Aris Persidis, From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors, Expert Review of Clinical Pharmacology, 2012, 5, 4, 413

    CrossRef